183 related articles for article (PubMed ID: 36346486)
1. Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.
Chen R; Qi Y; Huang Y; Liu W; Yang R; Zhao X; Wu Y; Li Q; Wang Z; Sun X; Wei B; Chen J
Breast Cancer Res Treat; 2023 Jan; 197(1):189-200. PubMed ID: 36346486
[TBL] [Abstract][Full Text] [Related]
2. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
Asogan AB; Hong GS; Arni Prabhakaran SK
Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
Chen X; Yuan Y; Gu Z; Shen K
Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
[TBL] [Abstract][Full Text] [Related]
4. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.
Chen X; Sun L; Mao Y; Zhu S; Wu J; Huang O; Li Y; Chen W; Wang J; Yuan Y; Fei X; Jin X; Shen K
BMC Cancer; 2013 Aug; 13():390. PubMed ID: 23957561
[TBL] [Abstract][Full Text] [Related]
5. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
6. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
[TBL] [Abstract][Full Text] [Related]
7. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
[TBL] [Abstract][Full Text] [Related]
8. Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.
Shanmugalingam A; Hitos K; Hegde S; Al-Mashat A; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
Breast Cancer Res Treat; 2022 May; 193(1):151-159. PubMed ID: 35229238
[TBL] [Abstract][Full Text] [Related]
9. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
[TBL] [Abstract][Full Text] [Related]
10. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
[TBL] [Abstract][Full Text] [Related]
11. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).
Arnedos M; Nerurkar A; Osin P; A'Hern R; Smith IE; Dowsett M
Ann Oncol; 2009 Dec; 20(12):1948-52. PubMed ID: 19570962
[TBL] [Abstract][Full Text] [Related]
12. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
13. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.
Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
[TBL] [Abstract][Full Text] [Related]
15. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
[TBL] [Abstract][Full Text] [Related]
16. The appropriate number of preoperative core needle biopsy specimens for analysis in breast cancer.
Sun T; Zhang H; Gao W; Yang Q
Medicine (Baltimore); 2021 Apr; 100(14):e25400. PubMed ID: 33832135
[TBL] [Abstract][Full Text] [Related]
17. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients.
Tamaki K; Sasano H; Ishida T; Miyashita M; Takeda M; Amari M; Tamaki N; Ohuchi N
Cancer Sci; 2010 Sep; 101(9):2074-9. PubMed ID: 20557310
[TBL] [Abstract][Full Text] [Related]
18. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
[TBL] [Abstract][Full Text] [Related]
19. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
[TBL] [Abstract][Full Text] [Related]
20. Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.
Rodriguez C; Suciu V; Poterie A; Lacroix L; Miran I; Boichard A; Delaloge S; Deneuve J; Azoulay S; Mathieu MC; Valent A; Michiels S; Arnedos M; Vielh P
Mol Oncol; 2016 Nov; 10(9):1430-1436. PubMed ID: 27555543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]